0000950170-24-010798.txt : 20240202 0000950170-24-010798.hdr.sgml : 20240202 20240202190343 ACCESSION NUMBER: 0000950170-24-010798 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240130 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simpson Adam K. CENTRAL INDEX KEY: 0001873839 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40655 FILM NUMBER: 24593446 MAIL ADDRESS: STREET 1: C/O ICOSAVAX, INC. STREET 2: 1616 EASTLAKE AVENUE E., SUITE 208 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Icosavax, Inc. CENTRAL INDEX KEY: 0001786255 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1930 BOREN AVE., SUITE 1000 CITY: SEATTLE STATE: WA ZIP: 98101 BUSINESS PHONE: (206) 737-0085 MAIL ADDRESS: STREET 1: 1930 BOREN AVE., SUITE 1000 CITY: SEATTLE STATE: WA ZIP: 98101 4 1 ownership.xml 4 X0508 4 2024-01-30 0001786255 Icosavax, Inc. ICVX 0001873839 Simpson Adam K. C/O ICOSAVAX, INC. 1930 BOREN AVE., SUITE 1000 SEATTLE WA 98101 true true false false Chief Executive Officer true Common Stock 2024-02-01 4 G false 6532 0 D 525044 I By family trust Common Stock 2024-02-01 4 M false 15000 1.04 A 373657 D Common Stock 2024-02-01 4 S false 15000 15.2924 D 358657 D Common Stock 129032 I By family trust Common Stock 129032 I By family trust Stock Option (Right to Buy) 1.04 2024-02-01 4 M false 15000 0.00 D 2031-01-28 Common Stock 15000 191449 D The sales were effected pursuant to a Rule 10b5-1 instruction letter dated September 16, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.31. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter. /s/ Elizabeth Bekiroglu, Attorney-in-Fact 2024-02-02